European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.

MLA

Seferović, Petar M., et al. “European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure.” European Journal of Heart Failure, vol. 22, no. 2, Feb. 2020, pp. 196–213. EBSCOhost, https://doi.org/10.1002/ejhf.1673.

APA

Seferović, P. M., Coats, A. J. S., Ponikowski, P., Filippatos, G., Huelsmann, M., Jhund, P. S., Polovina, M. M., Komajda, M., Seferović, J., Sari, I., Cosentino, F., Ambrosio, G., Metra, M., Piepoli, M., Chioncel, O., Lund, L. H., Thum, T., De Boer, R. A., Mullens, W., & Lopatin, Y. (2020). European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. European Journal of Heart Failure, 22(2), 196–213. https://doi.org/10.1002/ejhf.1673

Chicago

Seferović, Petar M., Andrew J.S. Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S. Jhund, Marija M. Polovina, et al. 2020. “European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure.” European Journal of Heart Failure 22 (2): 196–213. doi:10.1002/ejhf.1673.